Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis

• Main Authors: Kao J., Tung S., Lee Y., Thongsawat S., Tanwandee T., Sheen I., Wu J., Li H., Brennan B., Zhou J., Le Pogam S., Najera I., Thommes J., Hill G.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85002152541&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/41509

© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: Chronic hepatitis C is an important public health problem in Asia. We evaluated the safety, efficacy, and pharmacokinetics of fixed-dose ritonavir-boosted danoprevir plus pegin...